Sanofi (SNY) Signs Deal for AI-Powered Drug Development

21.05.24 17:52 Uhr

Werte in diesem Artikel
Aktien

2.401,00 JPY -25,00 JPY -1,03%

88,32 EUR 1,13 EUR 1,30%

Indizes

7.628,6 PKT -42,8 PKT -0,56%

504,6 PKT -4,4 PKT -0,86%

4.907,3 PKT -40,4 PKT -0,82%

1.498,0 PKT -13,7 PKT -0,90%

3.519,6 PKT -17,6 PKT -0,50%

7.312,4 PKT 12,5 PKT 0,17%

5.769,6 PKT -37,2 PKT -0,64%

4.513,3 PKT -31,4 PKT -0,69%

Sanofi SNY announced that it has entered into a first-in-class artificial intelligence (AI) collaboration with Formation Bio and OpenAI to build AI-powered software to expedite the development of drugs.Formation Bio is a tech-driven, AI-native pharma company focused on bringing new treatments to patients with more efficient drug development, while OpenAI is an AI research and deployment company.Per the press release, the companies are collaborating to bring together data, software and tuned models aimed at developing custom, purpose-built solutions in the drug development lifecycle.Sanofi’s collaboration with Formation Bio and OpenAI for AI-driven drug development is the first of its kind within the pharma and life sciences industries.Shares of Sanofi have decreased 2.6% year to date against the industry’s rise of 15.3%.Image Source: Zacks Investment ResearchWith the help of this partnership with Formation Bio and OpenAI, Sanofi is looking to become the first pharmaceutical company substantially powered by AI.Sanofi is strongly deploying AI, data science and computational expertise to develop first and best-in-class medicines for patients who are looking for innovative treatments.We note that there is a huge potential for AI to accelerate and shape the future of drug development.Last month, Moderna MRNA entered into a collaboration with OpenAI to co-develop and advance mRNA medicines.With this deal, MRNA is looking to bring a new generation of medicines to patients in need.Moderna is looking to integrate generative AI to advance its broad and diverse portfolio of mRNA medicines and vaccines.Zacks Rank & Stocks to ConsiderSanofi currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the healthcare sector are Entera Bio Ltd. ENTX and ANI Pharmaceuticals, Inc. ANIP, both carrying a Zacks Rank #2 (Buy) at present.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.In the past 60 days, estimates for Entera Bio’s 2024 loss per share have narrowed from 75 cents to 25 cents. Year to date, shares of ENTX have surged 283.4%.ENTX’s earnings beat estimates in three of the trailing four quarters and missed the same once, the average surprise being 6.50%.In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.43 to $4.44. Year to date, shares of ANIP have jumped 12%.Earnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 53.90%.Buy 5 Stocks BEFORE Election DayBiden or Trump? Zacks is releasing a FREE Special Report, Profit from the 2024 Presidential Election (no matter who wins).Since 1950, presidential election years have been strong for the market. This report names 5 timely stocks to ride the wave of electoral excitement.They include a medical manufacturer that gained +11,000% in the last 15 years… a rental company absolutely crushing its sector… an energy powerhouse planning to grow its already large dividend by 25%... an aerospace and defense standout that just landed a potentially $80 billion contract… and a giant chipmaker building huge plants in the U.S. Don’t Wait. Download FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report Entera Bio Ltd. (ENTX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Ai

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Ai

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu Sanofi S.A.

Analysen zu Sanofi S.A.

DatumRatingAnalyst
04.06.2024Sanofi BuyUBS AG
03.06.2024Sanofi NeutralJP Morgan Chase & Co.
13.05.2024Sanofi SellDeutsche Bank AG
13.05.2024Sanofi BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
10.05.2024Sanofi BuyUBS AG
DatumRatingAnalyst
04.06.2024Sanofi BuyUBS AG
13.05.2024Sanofi BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
10.05.2024Sanofi BuyUBS AG
06.05.2024Sanofi BuyUBS AG
25.04.2024Sanofi BuyJefferies & Company Inc.
DatumRatingAnalyst
03.06.2024Sanofi NeutralJP Morgan Chase & Co.
10.05.2024Sanofi NeutralJP Morgan Chase & Co.
29.04.2024Sanofi NeutralJP Morgan Chase & Co.
25.04.2024Sanofi HaltenDZ BANK
18.04.2024Sanofi NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
13.05.2024Sanofi SellDeutsche Bank AG
29.04.2024Sanofi SellDeutsche Bank AG
20.02.2024Sanofi SellDeutsche Bank AG
06.02.2024Sanofi SellDeutsche Bank AG
02.02.2024Sanofi SellDeutsche Bank AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sanofi S.A. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"